Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTLaiba ImmadTue, August 11, 2026 at 2:31 PM GMT+2 6 min readPfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down very different paths. One is leveraging massive scale and aggressive cost-cutting to protect profits, while the other is absorbing heavy losses to fund a corporate transition into oncology under new leadership.Pfizer vs. BioNTech: Which Pharma Giant Is Better Positioned for the Post-COVID Era?Pfizer Inc. (NYSE:PFE): Execution and Cost-Cutting Offset COVID HeadwindsPfizer Inc. delivered a solid quarter, posting Q2 2026 revenues of $15.0 billion, a 1% operational increase year-over-year. Excluding Comirnaty and Paxlovid, revenue grew 5% operationally, fueled by strong performance in non-COVID products. Key drivers included Eliquis (up 19% operationally), Padcev (up 23%), Lorbrena (up 37%), and the Vyndaqel family (up 8%). Altogether, launched and acquired products surged 18% operationally. On the bottom line, Pfizer posted a reported loss per share of $(0.04) due to a $4.3 billion non-cash intangible asset impairment, but delivered Adjusted Diluted EPS of $0.77.To maintain financial momentum, Pfizer raised its full-year 2026 revenue guidance by $500 million to $60.5–$62.5 billion, reflecting a $1.5 billion outperform in non-COVID products offsetting lower COVID-19 sales (revised down to $4 billion from $5 billion). CEO Dr. Albert Bourla highlighted momentum across the obesity program and oncology portfolio. Furthermore, Pfizer announced an expansion of its productivity enhancement initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029. Pfizer reaffirmed full-year Adjusted EPS guidance of $2.80 to $2.00, which absorbs a $0.10 impact from its Innovent Biologics transaction. Capital allocation remains disciplined, with $5.3 billion reinvested into internal R&D, $4.9 billion paid out in dividends, and no share repurchases completed year-to-date as the company focuses on de-leveraging.BioNTech SE (NASDAQ:BNTX): Deepening Losses Amid a Leadership Hand-OffBioNTech SE faced a significantly tougher financial landscape as COVID-19 vaccine demand continued to fall. Q2 2026 revenues fell 59.5% year-over-year to €105.6 million (down from €260.8 million), driving the company's IFRS net loss to widen to €820.8 million, or €3.24 per diluted share. Driven by lower demand and timing, BioNTech cut its full-year 2026 revenue guidance to €1.6–€1.9 billion (down from €2.0–€2.3 billion). Despite commercial top-line pressure, BioNTech maintains a fortress balance sheet with €16.6 billion in cash, cash equivalents, and security investments.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info